Contract Services Clinical Research
Energenesis, Yoo Young Pharm Explore Korean Development of Diabetic Foot Ulcer Therapy
Energenesis Biomedical Co., Ltd. (TWSE: 6657) today announced that it has signed a Memorandum of Understanding ("MOU") with Yoo Young Pharm. Co., Ltd. ("YY...
October 07, 2026 | News
Thermo Fisher Proteomics Study Uncovers Over 2,500 New Genetic-Protein Associations
Thermo Fisher’s complementary proteomic technologies uncovered more than 2,500 new biological associations: Initial findings from the PRECISE-SG100...
October 06, 2026 | News
CSL, Alentis Forge $1.55B Partnership to Advance Lixudebart for Kidney and Liver Diseases
Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared CSL and Alentis Therapeuti...
October 06, 2026 | News
Bambusa Doses First Patient in Subcutaneous Cohort of Phase I BBT001 Trial
First patient dosed as Bambusa expands global development of its long-acting bispecific antibody targeting both IL-4Rα and IL-31 High-concentration ...
October 05, 2026 | News
Novartis Signs $7.8B RNA Therapeutics Deal With Abogen Biosciences
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager Agreement also gives Novartis exclusive options to license other...
October 05, 2026 | News
China Approves Jaypirca Across All Lines of Therapy for CLL/SLL
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
September 30, 2026 | News
iRegene Advances Off-the-Shelf Retinal Cell Therapy Into Clinical Trials in US and China
Following its Parkinson's disease program, iRegene advances another off-the-shelf cell therapy into clinical development in the U.S. and China. iReg...
September 30, 2026 | News
Innovent Expands Global Phase III IBI363 Trial to Non-Squamous NSCLC
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization...
September 29, 2026 | News
XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months
Viva-Thera makes its public debut with four modalities pursuing HIV prevention, treatment and cure, supported by XtalPi's platform capabilities. Viva-Th...
September 24, 2026 | News
Caliway’s CBL-514 Hits Phase II Pain-Reduction Endpoint in Dercum’s Disease
Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations...
September 23, 2026 | News
NewAmsterdam, Menarini Secure EU Approval for Obicetrapib-Based Ubeslo and Evlarco
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-s...
September 23, 2026 | News
Bestzyme Completes World’s First Automated Smart Production Line for Sweet Proteins
Bestzyme, a synthetic biology company under GenScript Biotech, announced the completion of the world's first dedicated, automated smart production li...
September 23, 2026 | News
IMPACT Therapeutics, Pharmanovia’s Senaparib Secures EU Panel Backing for Ovarian Cancer
MPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based...
September 21, 2026 | News
Daiichi Sankyo, AstraZeneca’s Enhertu Wins EU Panel Backing for Early Breast Cancer
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% vers...
September 21, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
